Adverse events · boys with DMD and left ventricular ejection fraction 45% or more
It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).
1 finding from 1 review
Proportion of patients achieving clinical response · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical response compared with placebo cigarettes (very low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · Patients with active Crohn's disease
Cannabis cigarettes (115 mg THC) showed no clear difference in CRP (mg/dL) at end of study compared with placebo cigarettes (low certainty).
1 finding from 1 review
Quality of life Short‐Form 36 health survey (SF‐36) · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes adverse events compared with placebo cigarettes (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg · women with uterine fibroids
GnRHa treatment showed no clear difference in preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal… compared with other medical therapies before any surgery (moderate certainty).
1 finding from 1 review
Preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg · women with uterine fibroids
SPRM may leads to higher preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg compared with placebo (low certainty).
1 finding from 1 review
Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women
Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review